A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Incyte Corporation
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Universitätsklinikum Hamburg-Eppendorf
Pfizer
Alliance for Clinical Trials in Oncology
Children's Oncology Group
Children's Oncology Group
Institute of Hematology & Blood Diseases Hospital, China
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
University Hospital Schleswig-Holstein
Sanofi
Gruppo Italiano Malattie EMatologiche dell'Adulto
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
St. Jude Children's Research Hospital
Prince of Wales Hospital, Shatin, Hong Kong
Gilead Sciences
University of Maryland, Baltimore
Therapeutic Advances in Childhood Leukemia Consortium
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Nanfang Hospital, Southern Medical University
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center
Celgene
St. Jude Children's Research Hospital
Sun Yat-sen University
Stanford University
Children's Oncology Group
Children's Oncology Group
Alliance for Clinical Trials in Oncology
Barbara Ann Karmanos Cancer Institute
Children's Oncology Group
Children's Oncology Group
National Heart, Lung, and Blood Institute (NHLBI)
Rutgers, The State University of New Jersey
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)